Hostname: page-component-54dcc4c588-64p75 Total loading time: 0 Render date: 2025-10-09T04:53:44.402Z Has data issue: false hasContentIssue false
  • English
  • Français

Progress in Understanding and Treating Parkinson's Disease

Published online by Cambridge University Press:  18 September 2015

André Barbeau
André Barbeau*
Affiliation:
Department of Neurobiology, Clinical Research Institute of Montreal
*
Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec, Canada
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

This review evaluates the long-term results of Levodopa therapy in Parkinson's disease upon quality of life, prolongation of survival and excess mortality. It also focuses on recent and new therapeutic approaches: Levodopa in comhindation with a Dopa-decarboxylase inhibitor or MAO-B inhibitor, dopamine agonists and an active tripeptide: L-prolyl-L-leucylglycine amide (M1F-I). It ends by looking at new avenues of etiological research in Parkinson's disease which may indicate specific accelerated ageing of catecholaminergic (pigmented) neuronal systems.

Information

Type
Recent Progress
Information
Canadian Journal of Neurological Sciences , Volume 3 , Issue 2 , May 1976 , pp. 81 - 84
Copyright
Copyright © Canadian Neurological Sciences Federation 1976

References

REFERENCES

Barbeau, A. (1961). Biochemistry of Parkinson’s disease. Excerpta Medica. I.C.S. 38: 152–153.Google Scholar
Barbeau, A. (1969). L-DOPA therapy in Parkinson’s disease: A critical review of nine years’ experience. Can. Med. Ass. J. 101: 791–800.Google ScholarPubMed
Barbeau, A. (1973). Aging and the extrapyramidal system. J. Amer. Geriat. Soc. 21: 145–149, 1973.CrossRefGoogle ScholarPubMed
Barbeau, A. (1975). Résultats à long terme de la L-Dopa dans la maladie de Parkinson. Union Méd. Canada 104: 3238, 1975.Google Scholar
Barbeau, A. (1975). Long-term assessment of Levodopa therapy in Parkinson’s disease. Can. Med. Ass. J. 112: 1379–1380.Google ScholarPubMed
Barbeau, A. (1975). Potentiation of Levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man. Lancet 2: 683–684.CrossRefGoogle ScholarPubMed
Barbeau, A. (1976). 6 years of high level Levodopa therapy in severely akinetic parkinsonian patients. Arch. Neurol., in press.CrossRefGoogle Scholar
Barbeau, A., Campanella, G.. Butterworth, R.F. and Yamada, K. (1975). Uptake and efflux of 14C-dopamine in platelets: Evidence for a generalized defect in Parkinson’s disease. Neurology 25: 1–9.CrossRefGoogle ScholarPubMed
Barbeau, A. and Mcdowell, F. H. (Eds.) (1970). L-DOPA and Parkinsonism. F. A. Davis Ltd., Philadelphia, pp. 1–433.Google Scholar
Barbeau, A. and Roy, M. (1976). Six-year results of treatment with Levodopa plus benzerazide in Parkinson’s disease. Neurology, in press.CrossRefGoogle ScholarPubMed
Barbeau, A., Roy, M. and Kastin, A. J. (1976). Double-blind evaluation of oral L-prolyl-L-leucyl-glycine amide in Parkinson’s disease. Can. Med. Ass. J. 114: 120–122.Google Scholar
Birkmayer, W. and Hornykiewicz, O. (1961). Der L-3,4-dioxyphenylalanin (Dopa) - Effekt bei der Parkinson akinese. Wien. Klin. Wschr. 73: 787–795, 1961.Google Scholar
Birkmayer, W. and Mentasti, M. (1967). Weitere experimentelle unter-suchungen “ber den catecholamin-stoffwechsel bei extrapyramidalen erkran-kungen (Parkinson und chorea syndrom). Arch. Psychiatr. Nervenkr. 210: 29–35.CrossRefGoogle Scholar
Birkmayer, W., Riederer, P.. Youdim, M. B. H. and Linauer, W. (1975). The potentiation of the anti-akinetic effect after L-DOPA treatment by an inhibitor of MAO-B, deprenil. J. Neural Transmission 36: 303–326.CrossRefGoogle ScholarPubMed
Blashko, H. and Muscholl, E. (Editors) (1972). Catecholamines Springer-Verlag, Berlin, pp. 1–1054.Google Scholar
Calne, D. B. (Editor) (1973). Progress in the treatment of Parkinsonism. Advances in Neurology, Vol. 3. Raven Press. New York. pp. 1–326.Google Scholar
Calne, D. B., Chase, T. N. and Barbeau, A. (Editors) (1975). Dopaminergic Mechanisms, Advances in Neurology. Vol. 9, Raven Press, New York, pp. 1–452.Google Scholar
Calne, D. B.. Teychenne, P. F. and Leigh, P. N. (1974). Treatment of Parkinsonism with Bromocriptine. Lancet 2: 1355–1356.CrossRefGoogle ScholarPubMed
Chase, T. N., Woods, A. C. Lipton, M. A. and Morris, C. E. (1974). Hypothalamic releasing factors and Parkinson’s disease. Arch. Neurol. 31: 55–56.CrossRefGoogle Scholar
Cotzias, G. C, Papavasiliou, P. S.. Fehling, C. Kaufman, B. and Mena, I. (1970). Similarities between neurologic effects of L-DOPA and apomorphine. New Engl. J. Med. 282: 31–33.CrossRefGoogle ScholarPubMed
Cotzias, G. C. Papavasiliou, P. S., Tolosa, E. S.. Mendez, J. S. and Bell-Midura, M. (1976). Treatment of Parkinson’s disease with aporphines — Possible role of growth hormone, New Engl. J. Med. 294: 567–572.CrossRefGoogle ScholarPubMed
Cotzias, G. C, Van Woert, M. H. and Schiffer, L. (1967). Aromatic amino acids and modifications of Parkinsonism. New Engl. J. Med. 276: 374–379.CrossRefGoogle ScholarPubMed
De Ajuriaguerra, (Editor) (1971). Monoamines, noyaux gris centraux et syndrome de Parkinson. Masson et Cie, Paris, pp. 1–585.Google Scholar
Duby, S. E., Cotzias, G. C, Papavasiliou, P. S. (1972). Injected apomorphine and orally administered Levodopa in Parkinsonism. Arch. Neurol. 27: 474–480.CrossRefGoogle ScholarPubMed
Fischer, P. A., Schneider, E., Jacobi, P. and Maxion, H. (1974). Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson’s syndrom. Europ. Neurol. 12: 360–368.CrossRefGoogle ScholarPubMed
Fuxe, K., Hokfelt, T. and Ungerstedt, U. (1970). Morphological and functional aspects of central monoamine neurons. Internat. Rev. Neurobiol. 13: 93–126, 1970.CrossRefGoogle Scholar
Hoehn, M. M. and Yahr, M. D. (1967). Parkinsonism: Onset, progression and mortality. Neurology 17: 427–435.CrossRefGoogle ScholarPubMed
Kastin, A. J. and Barbeau, A. (1972). Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson’s disease. Can. Med. Ass. J. 107: 1079–1081.Google ScholarPubMed
Livett, B. G. (1973). Histochemical visualization of peripheral and central adrenergic neurones. Br. Med. Bull. 29: 93–99.CrossRefGoogle ScholarPubMed
Markham, C. H., Treciokas, L. J. and Diamond, S. G. (1974). Parkinson’s disease and Levodopa-a five year follow-up and review. West. J. Med. 121: 188–206.Google Scholar
Marsden, C. D. and Parkes, J. D. (1976). “On-off’ effects in patients with Parkinson’s disease on chronic Levodopa therapy. Lancet 1: 292–296.CrossRefGoogle ScholarPubMed
McDowell, F. H. and Barbeau, A. (Editors) (1974).Second Canadian-American Conference on Parkinson’s Disease, Advances in Neurology Vol. 5, Raven Press, New York. pp. 1–512.Google Scholar
Nair, R. M. G., Kastin, A. J. anc Sch-ALLY, A. V. (1971). Isolation and structure of hypothalamic MSH release-inhibiting-hormone. Biochem. Biophys. Res. Commun. 43: 1376–1381.CrossRefGoogle Scholar
Plotnikoff, N. P. and Kastin, A. J. (1974). Oxotremorine antagonism by prolyl-leucyl-glycine amide administered by different routes and with several an-ticholinergics. Pharmacol. Biochem. Behav. 2: 417–424.CrossRefGoogle Scholar
Plotnikoff, N. P., Kastin, A. J., Anderson, M. S. and Schally, A. V. (1971) . Dopa potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF). Life Sci. 10: 1279–1283.CrossRefGoogle ScholarPubMed
Schwab, R. S., Amador, L. V. and Lettvin, J. Y. (1951). Apomorphine in Parkinson’s disease. Trans. Am. Neurol. Assoc. 76: 251–253.Google Scholar
Shuster, S., Burton, J. L., Thody, A. J., Plummer, N., Goolamali, S. K. and Bates, D. (1973). Melanocyte-stimulating hormone and parkinsonism. Lancet 1: 463–465.CrossRefGoogle ScholarPubMed
Thierry, A. M., Blanc, G., Sobel, A., Stinus, L. and Glowinski, J. (1973).Dopaminergic terminals in the rat cortex. Science 182: 499–501.CrossRefGoogle ScholarPubMed
Yahr, M. D. (1973). Treatment of Parkinsonism - The role of dopa decarboxylase inhibitors. Advances in Neurology, Vol. 2, Raven Press, New York, pp. 1–303.Google Scholar
Youdim, M.B.H., Collins, G. G. S., Sandler, M., Bevan-Jones, A.B., Pare, C. M. B. and Nicholson, W. j. (1972) . Human brain monoamine oxidase, multiple forms and selective inhibitors. Nature 236: 225–228.CrossRefGoogle ScholarPubMed